Journal article
SARS-CoV-2 takes its Toll
Nature immunology, Vol.22(7), pp.801-802
06/08/2021
DOI: 10.1038/s41590-021-00962-w
PMID: 34103714
Abstract
SARS-CoV-2 infection activates TLR2 signaling, which results in robust expression of proinflammatory cytokines that may contribute to disease in severe COVID-19. Inhibition of this signaling pathway represents a potential target for COVID-19 therapeutics.
Details
- Title: Subtitle
- SARS-CoV-2 takes its Toll
- Creators
- Alan SariolStanley Perlman
- Resource Type
- Journal article
- Publication Details
- Nature immunology, Vol.22(7), pp.801-802
- DOI
- 10.1038/s41590-021-00962-w
- PMID
- 34103714
- ISSN
- 1529-2908
- eISSN
- 1529-2916
- Grant note
- DOI: 10.13039/100000060, name: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases, award: PO1 AI060699, RO1 AI129269
- Language
- English
- Date published
- 06/08/2021
- Academic Unit
- Microbiology and Immunology; Stead Family Department of Pediatrics; Iowa Neuroscience Institute; Infectious Disease (Pediatrics)
- Record Identifier
- 9984087708002771
Metrics
27 Record Views